David A Berg

US Patent:

6692969, Feb 17, 2004

Filed:

Aug 11, 2000

Appl. No.:

09/637808

Inventors:

David E. Berg - Phoenix AZ 85022
Lois Hill Berg - Phoenix AZ 85022
Harold H. Harrison - Glen Rock NJ 07452

International Classification:

G01N 3386

US Classification:

436 69

Abstract:

This invention relates to a method for using a novel combination of assays to detect minimal activation of the coagulation response for determining whether a patient whose initial clinical evaluation indicates chronic fatigue syndrome, fibromyalgia, and related conditions can be treated using anticoagulant therapies. If activation of the coagulation response is detected, the present invention further includes treatment of CFS, FM or related condition using anticoagulant therapies.

US Patent:

7264936, Sep 4, 2007

Filed:

Aug 10, 2004

Appl. No.:

10/915018

Inventors:

David E. Berg - Phoenix AZ, US
Lois Hill Berg - Phoenix AZ, US
Harold H. Harrison - Scottsdale AZ, US

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

Methods for diagnosing and identifying genetic and metabolic factors associated with a physiologic procoagulant predisposition for and concurrent activation of the coagulation response in patients suffering from conditions such as chronic fatigue syndrome, fibromyalgia, Gulf War illness and cardiovascular disease are disclosed. Diagnostic assays utilized in the methods include measurement of blood levels of Protein C, Protein S, antithrombin, activated protein C resistance, prothrombin, plasminogen activator inhibitor-1, lipoprotein (a) and homocysteine. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.

US Patent:

20020037528, Mar 28, 2002

Filed:

Sep 28, 2001

Appl. No.:

09/966311

Inventors:

David Berg - Phoenix AZ, US
Lois Berg - Phoenix AZ, US
Harold Harrison - Scottsdale AZ, US

International Classification:

C12Q001/68
G01N033/567
C12Q001/56

US Classification:

435/006000, 435/007210, 435/013000

Abstract:

Methods for diagnosing and identifying genetic and metabolic factors associated with a physiologic procoagulant predisposition for and concurrent activation of the coagulation response in patients suffering from conditions such as chronic fatigue syndrome, fibromyalgia, Gulf War illness and cardiovascular disease are disclosed. Diagnostic assays utilized in the methods include measurement of blood levels of Protein C, Protein S, antithrombin, activated protein C resistance, prothrombin plasminogen activator inhibitor-1, lipoprotein (a) and homocysteine. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.

US Patent:

20040161812, Aug 19, 2004

Filed:

Oct 27, 2003

Appl. No.:

10/694033

Inventors:

David Berg - Phoenix AZ, US
Lois Berg - Phoenix AZ, US
Harold Harrison - Glen Rock NJ, US

International Classification:

C12Q001/56

US Classification:

435/013000

Abstract:

Disclosed is a method that includes steps of identifying conditions each associated with a low level activation of the coagulation response; conducting a clinical evaluation of a patient to determine a possibility that the patient has one of the conditions; if the clinical evaluation indicates the possibility that the patient has one of the conditions, providing a panel of different quantitative blood tests each capable of providing one of an abnormal result indicative of a low level activation of the coagulation response, and a normal result; performing the panel of different quantitative blood tests on the patient; obtaining a result for each of the blood tests; observing the results; and if at least two of the results are abnormal, using the abnormal results to assist in diagnosing the patient with the one of the conditions.